Acta Diabetologica

, Volume 48, Issue 1, pp 61–69 | Cite as

Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study

Original Article


To explore the clinical significance of seven diabetes-related serum microRNAs (miR-9, miR-29a, miR-30d, miR34a, miR-124a, miR146a and miR375) during the pathogenesis of type 2 diabetes (T2D), 56 subjects were recruited to this study: 18 cases of newly diagnosed T2D (n-T2D) patients, 19 cases of pre-diabetes individuals (impaired glucose tolerance [IGT] and/or impaired fasting glucose [IFG]) and 19 cases of T2D-susceptible individuals with normal glucose tolerance (s-NGT). Serum miRNAs were determined by real-time RT-PCR. Expression levels of single miRNAs and the expression signatures of miRNAs as a panel were analysed among the three groups. In n-T2D, all 7 miRNAs were significantly up-regulated compared with s-NGT and five were significantly up-regulated compared with pre-diabetes, while miRNA expression was not significantly different between s-NGT and pre-diabetes. By Canonical discriminant analysis, 70.6% of n-T2D subjects (12/17) were recognized by canonical discriminant function, while s-NGT and pre-diabetes subjects could not be discriminated from each other. Similar results were found in Hierarchical Clustering analysis based on the expression levels of all seven miRNAs. In different statistical analysis, miR-34a always showed the most significant differences. We conclude that the expression levels of seven diabetes-related miRNAs in serum were significantly elevated in n-T2D compared with pre-diabetes and/or s-NGT, and the latter two groups featured similar expression patterns of these miRNAs, suggesting that during the pathogenesis of T2D, the peripheral diabetes-related miRNAs have not changed significantly from s-NGT at pre-diabetic stage.


Type 2 diabetes (T2D) Impaired glucose tolerance (IGT) Impaired fasting glucose (IFG) Normal glucose tolerance (NGT) Circulating MicroRNA 


  1. 1.
    Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053PubMedCrossRefGoogle Scholar
  2. 2.
    Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812PubMedCrossRefGoogle Scholar
  3. 3.
    McCarthy MI, Zeggini E (2009) Genome-wide association studies in type 2 diabetes. Curr Diab Rep 9:164–171PubMedCrossRefGoogle Scholar
  4. 4.
    Palmer CN (2009) Novel insights into the etiology of diabetes from genome-wide association studies. Diabetes 58:2444–2447PubMedCrossRefGoogle Scholar
  5. 5.
    Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885PubMedCrossRefGoogle Scholar
  6. 6.
    Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev 8:657–662Google Scholar
  7. 7.
    Zeggini E (2007) A new era for Type 2 diabetes genetics. Diabet Med 24:1181–1186PubMedCrossRefGoogle Scholar
  8. 8.
    Lango H, Palmer CN, Morris AD et al (2008) Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 57:3129–3135PubMedCrossRefGoogle Scholar
  9. 9.
    Ji J, Wang XW (2009) New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther 8:1686–1693PubMedGoogle Scholar
  10. 10.
    Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006PubMedCrossRefGoogle Scholar
  11. 11.
    Gilad S, Meiri E, Yogev Y et al (2008) Serum microRNAs are promising novel biomarkers. PloS One 3:e3148PubMedCrossRefGoogle Scholar
  12. 12.
    Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518PubMedCrossRefGoogle Scholar
  13. 13.
    Huang Z, Huang D, Ni S et al (2009) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J CancerGoogle Scholar
  14. 14.
    Jackson DB (2009) Serum-based microRNAs: are we blinded by potential? Proc Natl Acad Sci USA 106:E5PubMedCrossRefGoogle Scholar
  15. 15.
    Tang X, Tang G, Ozcan S (2008) Role of microRNAs in diabetes. Biochim Biophys Acta 1779:697–701PubMedGoogle Scholar
  16. 16.
    Hennessy E, O’Driscoll L (2008) Molecular medicine of microRNAs: structure, function and implications for diabetes. Exp Rev Mol Med 10:e24CrossRefGoogle Scholar
  17. 17.
    Pandey AK, Agarwal P, Kaur K et al (2009) MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 23:221–232PubMedCrossRefGoogle Scholar
  18. 18.
    Tang X, Muniappan L, Tang G et al (2009) Identification of glucose-regulated miRNAs from pancreatic beta cells reveals a role for miR-30d in insulin transcription. RNA 15:287–293PubMedCrossRefGoogle Scholar
  19. 19.
    Baroukh N, Ravier MA, Loder MK et al (2007) MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic beta-cell lines. J Biol Chem 282:19575–19588PubMedCrossRefGoogle Scholar
  20. 20.
    Plaisance V, Abderrahmani A, Perret-Menoud V et al (2006) MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 281:26932–26942PubMedCrossRefGoogle Scholar
  21. 21.
    Poy MN, Eliasson L, Krutzfeldt J et al (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432:226–230PubMedCrossRefGoogle Scholar
  22. 22.
    He A, Zhu L, Gupta N et al (2007) Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3–L1 adipocytes. Mol Endocrinol 21:2785–2794PubMedCrossRefGoogle Scholar
  23. 23.
    Lovis P, Roggli E, Laybutt DR et al (2008) Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 57:2728–2736PubMedCrossRefGoogle Scholar
  24. 24.
    (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62–S67Google Scholar
  25. 25.
    Ji J, Zhao L, Budhu A et al (2010) Let-7 g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 52:690–697Google Scholar
  26. 26.
    Wong L, Lee K, Russell I et al (2007) Endogenous controls for real-time quantitation of miRNA using TaqMan MicroRNA assays. Macmillan Publishers Limited (all rights reserved), New YorkGoogle Scholar
  27. 27.
    Roggli E, Britan A, Gattesco S et al (2010) Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59:978–986Google Scholar
  28. 28.
    Feng B, Chen S, George B et al (2010) miR133a regulates cardiomyocyte hypertrophy in diabetes. Diabetes Metab Res Rev 26:40–49Google Scholar
  29. 29.
    Poy MN, Hausser J, Trajkovski M et al (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA 106:5813–5818PubMedCrossRefGoogle Scholar
  30. 30.
    Quinn GP, Keough MJ (2002) Experimental design and data analysis for biologists. Cambridge University Press, CambridgeGoogle Scholar
  31. 31.
    Berezikov E, Guryev V, van de Belt J et al (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120:21–24PubMedCrossRefGoogle Scholar
  32. 32.
    Bentwich I, Avniel A, Karov Y et al (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766–770PubMedCrossRefGoogle Scholar
  33. 33.
    Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20PubMedCrossRefGoogle Scholar
  34. 34.
    Wu Y, Li H, Loos RJ et al (2008) Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 57:2834–2842PubMedCrossRefGoogle Scholar
  35. 35.
    Ruchat S-M, Elks C, Loos R et al (2009) Association between insulin secretion, insulin sensitivity and type 2 diabetes susceptibility variants identified in genome-wide association studies. Acta Diabetol 46:217–226PubMedCrossRefGoogle Scholar
  36. 36.
    Zhao J, Bradfield JP, Zhang H et al (2010) Examination of all type 2 diabetes GWAS loci reveals HHEX-IDE as a locus influencing pediatric BMI. Diabetes 59:751–755Google Scholar
  37. 37.
    Lantz KA, Vatamaniuk MZ, Brestelli JE et al (2004) Foxa2 regulates multiple pathways of insulin secretion. J Clin Invest 114:512–520PubMedGoogle Scholar
  38. 38.
    Meissner T, Beinbrech B, Mayatepek E (1999) Congenital hyperinsulinism: molecular basis of a heterogeneous disease. Hum Mutat 13:351–361PubMedCrossRefGoogle Scholar
  39. 39.
    Dinneen SF, Maldonado D 3rd, Leibson CL et al (1998) Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care 21:1408–1413PubMedCrossRefGoogle Scholar
  40. 40.
    Meigs JB, Muller DC, Nathan DM et al (2003) The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 52:1475–1484PubMedCrossRefGoogle Scholar
  41. 41.
    Tirosh A, Shai I, Tekes-Manova D et al (2005) Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 353:1454–1462PubMedCrossRefGoogle Scholar
  42. 42.
    Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRefGoogle Scholar
  43. 43.
    Delahanty LM, Nathan DM (2008) Implications of the diabetes prevention programme and Look AHEAD clinical trials for lifestyle interventions. J Am Diet Assoc 108:S66–S72PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of EndocrinologyProvincial Hospital Affiliated to Shandong UniversityJinanPeople’s Republic of China
  2. 2.Liver Cancer Institute and Zhongshan HospitalFudan UniversityShanghaiPeople’s Republic of China
  3. 3.Shandong Provincial Tumour Hospital and Institute of OncologyJinanPeople’s Republic of China

Personalised recommendations